FDA Changes Bioequivalence Requirements For Vancomycin
ViroPharma, marketer of Lilly’s Vancocin, “strongly disagrees” with FDA’s decision and files a citizen petition challenging it.
ViroPharma, marketer of Lilly’s Vancocin, “strongly disagrees” with FDA’s decision and files a citizen petition challenging it.